Halozyme Therapeutics Inc (HALO) — Capital Reinvestment Ratio
Halozyme Therapeutics Inc (HALO) has a Capital Reinvestment Ratio of 0.02x as of September 2025, meaning it reinvests 0% of its operating cash flow ($178.60 Million) in capital expenditures ($3.03 Million). Check Halozyme Therapeutics Inc (HALO) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Halozyme Therapeutics Inc Capital Reinvestment Ratio (2006–2024)
This chart tracks Halozyme Therapeutics Inc's Capital Reinvestment Ratio across 7 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Halozyme Therapeutics Inc.
Annual Capital Reinvestment Ratio for Halozyme Therapeutics Inc (2006–2024)
Year-by-year Capital Reinvestment Ratio for Halozyme Therapeutics Inc from 2006 to 2024. See Halozyme Therapeutics Inc (HALO) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | $479.06 Million | $10.70 Million | ▼ -43.3% |
| 2023 | 0.04x | $388.57 Million | $15.29 Million | ▲ +96.5% |
| 2022 | 0.02x | $240.11 Million | $4.81 Million | ▲ +311.7% |
| 2021 | 0.00x | $299.44 Million | $1.46 Million | ▼ -89.2% |
| 2020 | 0.05x | $55.45 Million | $2.50 Million | ▲ +348.4% |
| 2017 | 0.01x | $134.05 Million | $1.35 Million | ▼ -80.5% |
| 2006 | 0.05x | $7.08 Million | $364.80K | — |